GNBT - BioPharma w/10x Potential - Cancer and Diabetes Treatments - Nasdaq Up List
31 Outubro 2019 - 11:51AM
InvestorsHub NewsWire
GNBT – BioPharma w/10x Potential –
Cancer and Diabetes Treatments – Nasdaq Up List
- Under $2 PPS With Potential To Over $10 In
Near Term
- Phase III Trials On Horizon For Cancer and
Diabetes
- Nasdaq Up List Targeted Before End Of
Year
- Dividend
Strategy
October 31, 2019 -- InvestorsHub NewsWire
-- via www.nextbigticker.com -- Generex
Biotechnology Corporation (www.generex.com) (GNBT) is
sitting on an explosive ROI opportunity with a price-per-share
(PPS) under $2.00 and a potential to see over $10.00 by the end of
this year. GNBT is simultaneously advancing multiple bull run
triggers – Phase III trials for cancer and diabetes treatments; A
pending Nasdaq up-listing, and stock dividend. The Nasdaq
up-list will bring GNBT an institutional investor base it does not
currently enjoy as a bulletin-board stock. Phase III
biopharma trials regularly drive a massive market-cap increase on
the magnitude of 10x making biopharma one of the top performing
sectors consistently outperforming other sectors. GNBT has
demonstrated a dividend strategy and has a dividend on the books
now pending the completion of its Nasdaq
up-list.
Global demand for Biopharmaceuticals is
projected to grow at a CAGR of 10.8% between 2018 and 2025. The
global market for biopharmaceuticals in 2019 is expected to reach
US$269.3 billion. The biopharmaceuticals market is driven
largely by an increase in the elderly population, a surge in the
prevalence of chronic diseases like cancer, HIV/AIDS and diabetes.
Biopharmaceuticals offer the potential to actually cure diseases
rather than merely treat the symptoms. Hence the market
demand for biopharmaceuticals.
Drug company valuations increase
exponentially over time. The valuations start to become interesting
when a company enters Phase II trials which GNBT is now well into.
Drug companies that transition from Phase II to Phase III regularly
see valuations go from under $100 million to over $1 billion. GNBT
is sitting at a market-cap today of approximately $70 million. It
takes a long time to develop drugs, and most of the value is
created after many years. GNBT is not a new company. It is a
20-year-old company that has upped its game and expanding into
managing healthcare networks in addition to continuing to develop
its portfolio of drugs. The healthcare management provides
GNBT a unique sustainability model not seen in other biopharma
companies. Yet another reason to make a bet on GNBT’s
long-term ROI potential.
GNBT is an investment opportunity worth
your time to explore.
DISCLAIMER: NextBigTicker.com (NBT)is
a third party publisher and news dissemination service
provider. NBT is NOT affiliated in any manner with any company
mentioned herein. NBT is news dissemination solutions provider and
are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. NBT's market updates, news alerts and corporate
profiles are NOT a solicitation or recommendation to buy, sell or
hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Generex Biotechnology (CE) (USOTC:GNBT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Generex Biotechnology Corporation (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Generex Biotechnology Corp. (QB)